Galaxy Brain Scientific's SCAN-Targeted Technology Redefines Parkinson's Treatment Through Precision Neural Circuit Stimulation
A landmark study published in Nature by Prof. Hesheng Liu of Galaxy Brain Scientific identified the somato-cognitive action network (SCAN) as the core dysfunction in Parkinson's disease, redefining it as a SCAN disorder rather than solely a basal ganglia movement disorder1
The international research collaboration analyzed precision functional neuroimaging data from over 800 participants across Galaxy Brain Scientific Inc., Washington University in St. Louis, Tsinghua University, Peking University, and Harvard University1
All existing effective Parkinson's therapies share a common mechanism:
they reduce abnormally high connectivity between the SCAN and deep brain regions, normalizing the circuit1
SCAN-targeted transcranial magnetic stimulation showed a 56% response rate after two weeks compared to only 22% for stimulation of adjacent brain areas, representing a 2.5-fold increase in effectiveness46
Galaxy Brain Scientific developed a proprietary personalized Brain Functional Sectors (pBFS) technology and precision circuit stimulation system capable of targeting the SCAN non-invasively with millimeter accuracy1
The company's China NMPA-approved software and hardware system enables individualized precision targeting and non-invasive TMS stimulation1
Galaxy Brain Scientific has begun a pivotal registration trial for Class III devices dedicated to treating Parkinson's disease and is expanding applications to other brain disorders including Autism and Alzheimer's Disease1
This precision approach potentially offers the ability to slow or reverse Parkinson's progression rather than just suppressing symptoms1
Sources:
1. https://www.biospace.com/press-releases/galaxy-brain-scientifics-technology-enables-landmark-parkinsons-study-published-in-nature-redefining-disease-mechanism
4. https://www.eurekalert.org/news-releases/1115173
6. https://www.sciencedaily.com/releases/2026/02/260208203013.htm